Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Patent
1996-07-26
2000-02-29
Knode, Marian C.
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
536 243, 536 245, 514 44, 435 6, C07H 2104, C12Q 168
Patent
active
060310863
ABSTRACT:
Replacement of the natural nucleotides with unnatural zwitterionic nucleotides having a cationic moiety tethered to the base (or analog thereof) results in oligodeoxynucleotides with diminished charge but undiminished ability to complex with DNA at low ionic strengths. We have now discovered that DNA can be made fully zwitterionic by introducing tethered cationic moieties to the bases without affecting duplex formation. The resulting oligonucleotides have the further advantages of being nuclease resistant.
REFERENCES:
patent: 5596091 (1997-01-01), Switzer
Lisziewicz et al., "Antisense Oligodeoxynucleotide Phosphorothioate Complementary to GAG mRNA Blocks Replication of Human Immunodeficiency Virus Type 1 in Humna Peripheral Blood Cells," Proc. National Academy Sciences USA, 91, 7942-7946 (Aug. 1994).
Yacyshyn et al., "A Placebo-Controlled Trial of ICAM-1 Antisense Oligonculeotide in the Treatment of Crohn's Disease," Gastroenterology, 114(6), 1133-1142 (Jun. 1998).
Zon, "Brief Overview of Control of Gene Expression by Antisense Oligonucleotides and In Vivo Applications," Molecular Neurobiology, 10(2-3), 219-229 (1995).
Bayever et al., "Systemic Administration of a Phosphorothioate Oligonucleotide with a Sequence Complementary to p53 for Acute Myelogenous Leukemia and Myelodysplastic Syndrome: Initial Results of a Phase I Trial," Antisense Research and Development, 383-390 (1993).
Bishop et al., "Phase I Trial of an Antisense Oligonucleotide OL(1)p53 in Hematologic Malignancies," J. Clinical Oncology, 14(4), 1320-1326 (Apr., 1996).
Morgan et al., "Clinical Protocol: Gene Therapy for AIDS Using Retroviral Mediated Gene Transfer to Deliver HIV-1 Antisense TAR and Transdominant Rev Protein Genes to Syngeneic Lymphocytes in HIV-1 Infected Identical Twins," Human Gene Therapy, 7, 1281-1306 (Jun. 20, 1996).
"ISIS Begins Phase II Trial of Second Antisense Cancer Drug," ISIS Pharmaceuticals, Inc. Press Release, Carlsbad, CA, Nov. 25, 1997.
"ISIS Crohn's Disease Drug Shows Evidence of Durable Remission, Steroid Sparing and Fistula Heal;ing Effects," ISIS Pharmaceuticals, Inc. Press Release, Carlsbad, CA, Jun. 10, 1998.
"ISIS and CIBA Vison Receive FDA Approval for CMV Retinitis Drug," ISIS Pharmaceuticals, Inc. Press Release, Carlsbad, CA, Aug. 28, 1998.
"ISIS Development Pipeline," ISIS Pharmaceuticals, Inc. Fact Sheet, Carlsbad, CA, Sep. 15, 1998.
"Hybridon Unblinds Clinical Trial Results of GEM.RTM. 91 Showing Activity Against Advanced HIV," Hybridon, Inc. News Release, Cambridge, MA, Sep. 10, 1998.
"Hybridon Moves Gem.RTM. 91 into Confirmatory Clinical Trial in Advanced HIV-Positive Patient," Hybridon, Inc. New Release, Cambridge, MA, Sep. 10, 1998.
Sikic et al., "Antisense Oligonucleotide Therapy Targeted to Protein Kinase C-.alpha. (ISIS 9521/CGP 54128A) by 21 Day Infusion: Results of the Phase I Trial and Activity in Ovarian Carcinomas," Proceedings Am. Soc. Clinical Oncology (34th Ann. Mtg.), 17, Abstr. No. 1654, p. 429a (May 16-19, 1998), Los Angeles, CA.
Von Hoff et al., "Phase I Pharmacokinetic (PK) Trial of a Protein Kinase C-.alpha. Antisense Oligonucleotide, ISIS 3521 (CGP 64128A), Administered Thrice Weekly," Proceedings Am. Soc. Clinical Oncology (34th Ann. Mtg.), 17, Abstr. No. 812, p. 211a (May 16-19, 1998), Los Angeles, CA.
O'Dwyer et al., "Phase I Pharmacokinetic/Pharmacodynamic Trial of Raf-1 Antisense ODN (ISIS 5132, CGP 69846A)," Proceedings Am. Soc. Clinical Oncology (34th Ann. Mtg.), 17, Abstr. No. 810, p. 210a (May 16-19, 1998), Los Angeles, CA.
Holmlund et al., "Phase I Trial Of c-RAF antisense Oligonucleotide ISIS 5132 (CGP 69846A) By 21-Day Continuous Intravenous Infusion (CIV) in Patients with Advanced Cancer," Proceedings Am. Soc. Clinical Oncology (34th Ann. Mtg.), 17, Abstr. No. 811, p. 210a (May 16-19, 1998), Los Angeles, CA.
Zon, "Oligonucleotide Analogues as Potential Chemotherapeutic Agents," Pharmaceutical Research, 5(9), 539-549 (1988).
Gura, "Antisense Has Growing Pains--Efforts to Develop Antisense Compounds for Cancer, AIDS, and Other Diseases Have Encountered Some Unexpected Questions About How the Drugs Really Work," Science, 270, 575-577 (Oct. 27, 1995).
Krieg et al., "CpG Motifs in Bacterial DNA Trigger Direct B-Cell Activation," Nature, 374, 546-549 (6 Apr. 1995).
Rojanasakul, "Antisense Oligonucleotide Therapeutics: Drug Delivery and Targeting," Advanced Drug Delivery Reviews, 18, 115-131 (1996).
Gewirtz et al., "Facilitating Oligonucleotide Delivery: Helping Antisense Deliver on Its Promise," Proc. Nat. Acad. Sci USA, 93, 3161-3163 (Apr. 1996).
Stull et al., "Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects," Pharmaceutical Research, 12(4), 465-483 (1995).
Roush, "Antisense Aims for Renaissance--Antisense Therapies, Once Plagued by Side Effects and Mysterious Failures, Have Now Shed Their Troubled Image, Thanks to Encouraging New Clinical Results and Basic Research on Past Problems," Science, 276, 1992-1193 (May 23, 1997).
Robertson, "Crohn's Trial Shows the Pros of Antisense," Nature Biotechnology, 15, 209 (Mar. 15, 1997).
Crane L. Eric
Knode Marian C.
The Regents of the University of California
LandOfFree
Antisense oligonucleitide containing compositions and method of does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense oligonucleitide containing compositions and method of , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense oligonucleitide containing compositions and method of will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-684124